Oxford Biomedica plc
OXB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.15 | 0.03 | -0.00 |
| FCF Yield | 0.25% | -3.27% | -14.09% | -13.21% |
| EV / EBITDA | -63.51 | 98.24 | -17.35 | -1.96 |
| Quality | ||||
| ROIC | -16.52% | -5.62% | -17.22% | -63.19% |
| Gross Margin | 43.23% | 44.52% | 35.34% | 38.27% |
| Cash Conversion Ratio | -0.09 | 1.11 | 1.21 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.34% | 12.88% | 18.64% | 20.61% |
| Free Cash Flow Growth | 105.81% | 66.98% | -56.73% | -113.64% |
| Safety | ||||
| Net Debt / EBITDA | -8.46 | 9.58 | -1.47 | -0.07 |
| Interest Coverage | -3.58 | -1.79 | -7.04 | -37.05 |
| Efficiency | ||||
| Inventory Turnover | 2.67 | 3.19 | 1.98 | 2.23 |
| Cash Conversion Cycle | 82.21 | 56.84 | 55.22 | 47.23 |